Rebecca Miksad, MD
Associate Professor, Medicine
Biography
Rebecca Miksad is a medical oncologist and health outcomes researcher who serves as senior medical director at Flatiron Health. In this role, Rebecca focuses on generating real-world evidence, establishing regulatory-grade quality standards and contributing to the development of clinically-relevant methods to real-world data evaluation and analyses.
Rebecca maintains a clinical practice at Boston Medical Center. A nationally recognized clinician and researcher, Rebecca regularly publishes in leading medical journals, serves on national committees and lectures internationally.
Prior to joining Flatiron Health, Rebecca was an assistant professor at Harvard Medical School, senior scientist at the Institute for Technology Assessment at Massachusetts General Hospital, and director of gastrointestinal oncology and gastrointestinal oncology clinical trials at Beth Israel Deaconess Medical Center (BIDMC). Rebecca’s academic research focused on improving cancer treatment decision-making through better characterization of patient outcomes and increasing relevance of clinical trial endpoints. Rebecca earned a BA cum laude in economics from Harvard University and an MD with honors in research from Cornell University. She was a resident in internal medicine at Cornell University/New York-Presbyterian Hospital, and completed hematology and medical oncology fellowships at Harvard Medical School/BIDMC. Rebecca earned a MMS from Harvard Medical School and an MPH in Clinical Effectiveness from the Harvard School of Public Health in clinical effectiveness (with an emphasis on decision science). She also completed a post-doctoral fellowship in the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training (PCORT).
Education
- Cornell University, MD
- Harvard University, MMS/MMSc
- Harvard School of Public Health, MPH
- Harvard University, BA
Publications
- Published on 1/10/2025
Miksad RA, Sarkar S. Evaluating Cancer Screening in the Era of Advanced Causal Inference Methods: Innovation, Adherence, and Health Equity Considerations. JCO Clin Cancer Inform. 2025 Jan; 9:e2400214. PMID: 39792989.
Read at: PubMed - Published on 11/1/2024
Miksad RA. Real-World Evidence in Regulatory Decision Making: Time for Evidence Integration. Clin Pharmacol Ther. 2024 Nov; 116(5):1153-1155. PMID: 39404680.
Read at: PubMed - Published on 7/1/2024
Canavan ME, Wang X, Ascha MS, Miksad RA, Showalter TN, Calip GS, Gross CP, Adelson KB. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncol. 2024 Jul 01; 10(7):887-895. PMID: 38753341.
Read at: PubMed - Published on 6/1/2024
Miksad RA, Calip GS. Future of Cancer Treatment Guidelines: Integrating Real-World Insights for Equitable Cancer Care. JCO Clin Cancer Inform. 2024 Jun; 8:e2400081. PMID: 38959447.
Read at: PubMed - Published on 5/1/2024
Miksad RA, Ryals CA. The US Food and Drug Administration Dual Mandate for Rapid Drug Review and Equity. JAMA Netw Open. 2024 May 01; 7(5):e2411447. PMID: 38691364.
Read at: PubMed - Published on 1/9/2024
Vidal GA, Jain N, Fisher A, Sheinson D, Lofgren KT, Ma E, Yu E, Comment L, Miksad R, Sincan M, Martin RL, Zuniga R, Daniel D. Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer Treated in the US Community Setting. JCO Oncol Pract. 2024 Mar; 20(3):370-377. PMID: 38194619.
Read at: PubMed - Published on 8/31/2023
Guadamuz JS, Wang X, Ryals CA, Miksad RA, Snider J, Walters J, Calip GS. Socioeconomic status and inequities in treatment initiation and survival among patients with cancer, 2011-2022. JNCI Cancer Spectr. 2023 Aug 31; 7(5). PMID: 37707536.
Read at: PubMed - Published on 6/20/2023
Canavan M, Wang X, Ascha M, Miksad R, Showalter TN, Calip G, Gross CP, Adelson K. End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting. J Clin Oncol. 2023 Oct 20; 41(30):4729-4738. PMID: 37339389.
Read at: PubMed - Published on 6/1/2023
Goyal G, Lau KW, Wang X, Davidoff AJ, Huntington SF, Jamy O, Calip G, Shah H, Stephens DM, Miksad R, Parikh RB, Takvorian S, Neparidze N, Seymour EK. The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Netw Open. 2023 Jun 01; 6(6):e2316642. PMID: 37273206.
Read at: PubMed - Published on 3/21/2023
Abou-Alfa GK, Wang X, Parrinello CM, Gossai A, Kim R, Magee K, Miksad RA. Association between posttreatment a-fetoprotein reduction and outcomes in real-world US patients with advanced hepatocellular carcinoma. Cancer. 2023 Jul 01; 129(13):2064-2074. PMID: 36942492.
Read at: PubMed
View 87 more publications: View full profile at BUMC